OncoCyte Corp (OCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OncoCyte Corp (OCX) has a cash flow conversion efficiency ratio of -0.573x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($10.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OncoCyte Corp net asset quality index to measure how much of total assets are equity-financed.
OncoCyte Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how OncoCyte Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OncoCyte Corp cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
OncoCyte Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OncoCyte Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
La Kaffa International Co Ltd
TWO:2732
|
0.106x |
|
Raute Oyj
HE:RAUTE
|
-0.095x |
|
Federal Mogul Izmit Piston ve Pim Uretim Tesisleri AS
IS:FMIZP
|
0.067x |
|
Bionet
TWO:1784
|
0.013x |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
0.063x |
|
Bon Fame Co Ltd
TWO:8433
|
0.059x |
|
Eaton Vance Senior Income Closed Fund
NYSE:EVF
|
0.033x |
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
-0.004x |
Annual Cash Flow Conversion Efficiency for OncoCyte Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of OncoCyte Corp from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see OncoCyte Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +285.17% |
| 2023-12-31 | $25.59 Million | $-23.32 Million | -0.911x | +31.42% |
| 2022-12-31 | $34.29 Million | $-45.57 Million | -1.329x | -141.12% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more